Trial Profile
An Open-label Extension to a 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in Patients With Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2016
Price :
$35
*
At a glance
- Drugs Amilomotide (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Novartis
- 15 Jul 2016 New trial record